Q3 EPS Estimates for Mainz Biomed Increased by Analyst

Mainz Biomed NV (NASDAQ:QUCY) – Litchfield Hills Research raised their Q3 2026 earnings per share (EPS) estimates for Mainz Biomed in a research note issued on Tuesday, August 18th. Litchfield Hills Research analyst T. O’neill now expects that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.18). Litchfield Hills Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($1.12) per share. Litchfield Hills Research also issued estimates for Mainz Biomed’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.49) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.19) EPS, Q1 2028 earnings at ($0.03) EPS, Q2 2028 earnings at ($0.01) EPS and FY2028 earnings at ($0.02) EPS.

QUCY has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mainz Biomed in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Finally, Zacks Research raised shares of Mainz Biomed to a “hold” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Mainz Biomed Price Performance

QUCY stock opened at $1.44 on Thursday. Mainz Biomed has a 52 week low of $0.30 and a 52 week high of $4.93. The company has a market cap of $21.11 million, a P/E ratio of -0.14 and a beta of 2.31. The stock’s 50-day moving average is $1.42.

Key Mainz Biomed News

Here are the key news stories impacting Mainz Biomed this week:

• Positive Sentiment: Litchfield Hills raised its FY2026 EPS forecast to a loss of $0.49 from a loss of $1.12, while increasing its FY2027 estimate to a loss of $0.19 from $0.55 and its FY2028 estimate to a loss of $0.02 from $0.07. Although Mainz Biomed is still expected to lose money, the revised forecasts indicate materially narrowing losses.
• Positive Sentiment: Quarterly estimates were also improved: Q3 2026 EPS was raised to a loss of $0.08 from $0.18, Q4 2026 to a loss of $0.06 from $0.17, and several 2027 and 2028 quarterly forecasts were reduced to smaller losses. This could reinforce investor expectations for improving operating performance.
• Neutral Sentiment: The revisions came from a single research firm and concern future estimates rather than reported results, new contracts, financing, or clinical developments. Investors may therefore treat the update as a sentiment catalyst rather than confirmation of a fundamental turnaround.
• Negative Sentiment: Mainz Biomed remains unprofitable, with the broader consensus calling for a current full-year loss of $1.12 per share. The company’s small market capitalization and high beta also indicate elevated volatility and execution risk.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.